The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel
Status:
Completed
Trial end date:
2019-07-28
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double-blind, triple-dummy, parallel-controled,
dose-exploration phase II trial. Patients with coronary atherosclerotic heart disease and
planned percutaneous coronary intervention （PCI） will be randomized after informed consent,
in a 1:1:1:1 ratio to the following treatment groups: Experimental group 1 : Vicagrel 20mg
loading followed by 5mg/day for 28 days; Experimental group 2 : Vicagrel 24mg loading
followed by 6mg/day for 28 days; Experimental group 3 : Vicagrel 30mg loading followed by
7.5mg/day for 28 days; Control group : Clopidogrel 300mg loading followed by 75mg/day for 28
days. The primary purpose of this trial is to evaluate the efficacy, safety of vicagrel
antiplatelet therapy and explore dose in patients with coronary atherosclerotic heart disease
during and after PCI compared with clopidogrel.